A case of natural killer cell monoclonal expansion during efalizumab treatment in a patient with psoriasis.
Caproni
M
M
Volpi
W
W
Chiarini
C
C
Antiga
E
E
Giomi
B
B
Fabbri
P
P
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000187:drug effects*; D008218:Lymphocytosis / Q000139:chemically induced*; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; C472181:efalizumab